more aggressive treatment of patients with intermittent claudication

December 2000

Experts now recommend more aggressive treatment of patients with intermittent claudication...to reduce the risk of MI and stroke.

Treatment usually focuses on relieving symptoms.

Managing the underlying atherosclerosis is often overlooked... even though 70% of these patients die from cardiovascular disease.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

fibromyalgia
take phenylpropanolamine off the market
Infectious Diseases shortage of ADULT tetanus-diphtheria vaccine
Infectious Diseases Tamiflu is approved to PREVENT flu
Infectious Diseases You'll see two new HIV meds
Gastroenterology Lotronex (alosetron) off the market
Gastroenterology Colazal (KOL-a-zal), a new drug for ulcerative colitis
Cardiology more aggressive treatment of patients with intermittent claudication
Cardiology increasing potassium to lower the risk of hypertension and stroke
Cardiology monitoring patients more closely for hypokalemia
Lupus DHEA (dehydroepiandrosterone) is useful for treating lupus
Women's Health testosterone for women
Diabetes more focus on lowering POSTPRANDIAL glucose
Diabetes new study suggests that glyburide can be used for treating gestational diabetes
Multiple Sclerosis Novantrone (mitoxantrone) for multiple sclerosis

Anticoagulants Lovenox (enoxaparin) is now approved to prevent deep vein thrombosis in certain MEDICAL patients
Anticoagulants new low-molecular-weight heparin called Innohep